BioPharma Resources

Drug Trial Radar · NCT07037459

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 5,056 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,056

Planned (sponsor's estimate)

Start

Jun 25, 2025

Primary completion

Jun 30, 2028

Study completion Sep 29, 2030

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jun 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

Conditions

  • Heart Failure With Preserved Ejection Fraction
  • Heart Failure With Mildly Reduced Ejection Fraction
  • Obesity

Interventions

  • Maridebart cafraglutideDrug

    Maridebart cafraglutide will be administered SC.

  • PlaceboDrug

    Placebo will be administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of a Composite Endpoint Consisting of: CV Death or HF EventsTime frame: Up to approximately 35 months

Locations

686 sites in 35 countries. Site status is shown where the registry gives one.

  • University of Alabama Saint Vincent's Birmingham

    Birmingham, Alabama · Recruiting

  • SEC Clinical Research

    Dothan, Alabama · Recruiting

  • Eastern Shore Research Institute

    Fairhope, Alabama · Recruiting

  • Huntsville Clinical Research, LLC

    Huntsville, Alabama · Recruiting

  • HonorHealth

    Phoenix, Arizona · Terminated

  • Medical Advancement Centers of Arizona

    Phoenix, Arizona · Recruiting

  • Pima Heart and Vascular Clinical Research

    Tucson, Arizona · Recruiting

  • Yuma Clinical Trials

    Yuma, Arizona · Recruiting

  • Arkansas Cardiology

    Little Rock, Arkansas · Recruiting

  • National Heart Institute

    Beverly Hills, California · Recruiting

  • Valley Clinical Trials, LLC dba Flourish Research

    Covina, California · Recruiting

  • National Institute of Clinical Research

    Huntington Beach, California · Recruiting

  • 310 Clinical Research

    Inglewood, California · Recruiting

  • Radin Cardiovascular Medical Group

    Newport Beach, California · Recruiting

  • Valley Clinical Trials

    Northridge, California · Recruiting

  • University of California Irvine

    Orange, California · Recruiting

  • Empire Clinical Research

    Pomona, California · Recruiting

  • San Diego Cardiac Center

    San Diego, California · Recruiting

  • Kaiser Permanente

    San Francisco, California · Recruiting

  • NorthBay Clinical Research LLC

    Santa Rosa, California · Recruiting

  • Manshadi Heart Institute

    Stockton, California · Recruiting

  • Cardiology Associates of Fairfield County PC

    Stamford, Connecticut · Recruiting

  • Orlando Heart and Vascular Institute

    Altamonte Springs, Florida · Recruiting

  • D and H Tamarac Research Center

    Aventura, Florida · Recruiting

  • Excel Medical Clinical Trials

    Boca Raton, Florida · Recruiting

  • South Palm Cardiovascular Associates

    Boynton Beach, Florida · Recruiting

  • Cardiovascular and Vein Center of Florida

    Bradenton, Florida · Terminated

  • Millennium Medical Research

    Coral Gables, Florida · Recruiting

  • Elite Cardiac Research Center LLC

    Hialeah, Florida · Recruiting

  • Encore Medical Research LLC

    Hollywood, Florida · Recruiting

  • Nature Coast Clinical Research

    Inverness, Florida · Recruiting

  • East Coast Institute for Research

    Jacksonville, Florida · Recruiting

  • First Coast Cardiovascular Institute PA

    Jacksonville, Florida · Recruiting

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida · Recruiting

  • Clearwater Cardiovascular Consultants

    Largo, Florida · Recruiting

  • Ocala Cardiovascular Research

    Ocala, Florida · Recruiting

  • AdventHealth Orlando

    Orlando, Florida · Recruiting

  • Orlando Health Heart Institute

    Orlando, Florida · Recruiting

  • Ormond Beach Clinical Research

    Ormond Beach, Florida · Recruiting

  • Broward Research Center

    Pembroke Pines, Florida · Recruiting

Showing 40 of 686 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.